Genetic Ancestry for Sleep Research: Leveraging Health Inequalities to Identify Causal Genetic Variants

Bharati Prasad, MD, MS, Richa Saxena, PhD, Namni Goel, PhD, Sanjay R. Patel, MD, MS

PII: S0012-3692(18)30471-9
DOI: 10.1016/j.chest.2018.03.024
Reference: CHEST 1637

To appear in: CHEST

Received Date: 29 January 2018
Revised Date: 2 March 2018
Accepted Date: 19 March 2018

Please cite this article as: Prasad B, Saxena R, Goel N, Patel SR, Genetic Ancestry for Sleep Research: Leveraging Health Inequalities to Identify Causal Genetic Variants, CHEST (2018), doi: 10.1016/j.chest.2018.03.024.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
INVITED REVIEW  

Word Count 4,014, Ref 129

Title: Genetic Ancestry for Sleep Research: Leveraging Health Inequalities to Identify Causal Genetic Variants

Bharati Prasad MD, MS1, Richa Saxena PhD2,3, Namni Goel PhD4, Sanjay R. Patel MD, MS5

1 Department of Medicine, University of Illinois at Chicago and Jesse Brown VA Medical Center, Chicago, IL

2. Center for Genomic Medicine and Department of Anesthesia, Pain, and Critical Care Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA

3. Program in Medical and Population Genetics, Broad Institute, Cambridge, MA

4. Division of Sleep and Chronobiology, Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA

5. Department of Medicine, University of Pittsburgh, Pittsburgh PA

Corresponding Author:
Bharati Prasad, MD, MS
840 S Wood Street, MC 719
Chicago, IL 606012
bpradsad@uic.edu

Conflicts of Interest – SRP has received grant funding, through his institution, from the ResMed Foundation, the American Sleep Medicine Foundation, Bayer Pharmaceuticals and Philips Respironics. He has served as a consultant for Coviden. All others declare no conflicts of interest.
**Keywords:** Health Inequalities, Apnea, Sleep, Genetic Ancestry

**Abbreviations:** OSA = obstructive sleep apnea, AA = African American, HA = Hispanic American, EA = European American, REM = rapid eye movement, OR = odds ratio, AHI = apnea-hypopnea index, SES = socioeconomic status, HLA = human leukocyte antigen, MSLT = multiple sleep latency test, CRSD = circadian rhythm sleep disorders, GWAS = genome-wide association study
Abstract:

Recent evidence has highlighted the health inequalities in sleep behaviors and sleep disorders that adversely impact outcomes in select populations, including African Americans and Hispanic Americans. Race-related sleep health inequalities are ascribed to differences in multilevel and interlinked health determinants, such as sociodemographic factors, health behaviors and biology. African Americans and Hispanic Americans are admixed populations whose genetic inheritance combines two or more ancestral populations originating from different continents. Racial inequalities in admixed populations can be parsed into relevant groups of mediating factors (environmental versus genetic) with the use of measures of genetic ancestry, the proportion of an individual’s genetic make-up that comes from each of the major ancestral continental populations. This review describes sleep health inequalities in African Americans and Hispanic Americans and considers the potential utility of ancestry studies to exploit these differences to gain insight into the genetic underpinnings of these phenotypes. The inclusion of genetic approaches in future studies of admixed populations will allow greater understanding of the potential biological basis of race-related sleep health inequalities.
Sleep Health Inequalities: Introduction and Current Relevance

Sleep science has evolved rapidly in the recent decades, from refining methods to measure sleep in humans to gaining understanding of the pathophysiology and significant health impact of sleep disorders. This knowledge has led to the realization that remarkable health inequalities exist in sleep behaviors and sleep disorders. The World Health Organization (WHO) defines health inequalities “as differences in health status or in the distribution of health determinants between different populations” that is attributable to biological or sociocultural (voluntary) variations. A multitude of important health determinants exist in all populations with complex interrelationships, including socioeconomic status, literacy, geographic location, age, gender, race, individual behavior and biology. Accumulating evidence highlights the association of self-identified race with sleep health inequalities. Racial differences in health outcomes are often due to cultural, social, economic, and environmental inequalities that have persisted for generations. For example, neighborhood disadvantage has been found to be a risk factor for pediatric obstructive sleep apnea (OSA), and acculturation has important effects on sleep duration. However, in certain cases, racial inequalities can also be due to heritable biological differences in risk that have a genetic underpinnning. If the frequency of a genetic risk factor varies substantially across ancestral populations originating from different continents (e.g., Africans, Europeans, Native Americans), this variability can be exploited through the study of admixed populations whose genetic inheritance combines two or more ancestral populations. By correlating phenotype with genetic inheritance from the high-risk ancestral population, the location of the predisposing genetic alleles can be more readily identified. Thus, genetic studies of admixed populations (those who have descended from more than one ancestral population) can be a powerful tool for understanding the genetic underpinnings of biological traits including sleep-related phenotypes. To the extent that biology (rather than social, cultural, environmental,
and economic differences) underlies racial inequalities, genetic studies of admixed populations may also provide insights into the causes of racial health inequalities.

In this review, we discuss the current evidence on racial health inequalities in common sleep disorders focusing on reports in admixed populations in particular: African Americans, (AAs) who have a mixture of African and European ancestry, and Hispanic Americans (HAs), who have a mixture of African, European, and Native American ancestry compared to European Americans (EAs). Further, we outline how inclusion of genetic ancestry and techniques such as admixture mapping in association studies can improve scientific inference and identify novel genetic susceptibility loci contributing to variability in sleep phenotypes.

Inequalities in Obstructive Sleep Apnea

Obstructive sleep apnea (OSA) is a chronic disease with a rising prevalence and considerable attendant morbidity\textsuperscript{8,9}. Similar to other chronic diseases such as hypertension, there is significant heterogeneity among individuals with OSA in terms of pathophysiology and health outcomes\textsuperscript{10,11}. An underlying factor that contributes to this heterogeneity is racial inequalities in prevalence, risk, and outcomes of OSA (summarized in Table 1). Epidemiological studies in the United States report the prevalence of OSA is greater among AAs and HAs compared to EAs. The relative risk of OSA in AAs is moderated by age, with the highest risk being noted in children and a resurgence of risk after the age of 65 years\textsuperscript{4,12-15}. The conflicting data regarding higher prevalence in middle-aged AAs may be due to the underrepresentation of minorities in larger prospective cohorts and the use of different methods to define OSA, from questionnaires to different quantitative measures\textsuperscript{16,17}. An important replicated finding is that AAs have more severe OSA, based on quantitative metrics such as apnea hypopnea index (AHI) and oximetry, after adjustment for obesity\textsuperscript{18-21}. However, these studies were performed in clinical populations where bias related to access to care and delays in diagnosis may have confounded
the results\textsuperscript{22}. While this inequality has not been specifically examined in population-based cohorts, a similar trend is suggested by the Multi-Ethnic Study of Atherosclerosis (MESA), in which the odds ratios (ORs) for mild, moderate and severe OSA in AAs compared to EAs showed a linear trend towards increasing risk from 1.03 to 1.35\textsuperscript{4}. In fact, a statistically significant increase in risk was observed only for symptomatic OSA regardless of severity, suggesting a higher burden of disease\textsuperscript{4}. An older meta-analysis indicates that the independent effect of AA race on OSA risk and severity is small (effect sizes 0.13 and 0.10, respectively) but AAs with OSA have significantly shorter sleep duration (effect size -0.30)\textsuperscript{23}. Considering the chronic complex nature of OSA, with multiple fixed (age, sex, craniofacial anatomy) and modifiable (obesity) risk factors, this effect size is likely to be clinically significant\textsuperscript{24,25}.

There are fewer comparative studies on OSA prevalence between HAs and EAs. A previous report from a community cohort indicated a three-fold higher prevalence of moderate to severe OSA in HAs\textsuperscript{16}. In the MESA cohort, HAs had higher risk of mild, moderate and severe OSA (OR 1.6, 1.9, and 2.1, respectively). In contrast with observations in AAs, the prevalence of symptomatic OSA was not significantly higher in HAs\textsuperscript{4}. A recent report from the large Hispanic Community Health Study found the prevalence of OSA (approximately 26\%, 10\% and 4\% for mild, moderate and severe disease, respectively) to be at least as high as studies from predominantly EA cohorts\textsuperscript{8,26}. This study used home sleep apnea testing to assess OSA and included participants of seven Hispanic/Latino backgrounds, and significant differences in the prevalence of moderate to severe OSA were found in men across diverse Hispanic backgrounds even after adjustment for age and obesity. Elderly and post-stroke HAs are at higher risk for OSA compared to their EA counterparts\textsuperscript{27,28}. In contrast, data from a community pediatric cohort found no difference in the prevalence of OSA between HA and EA children\textsuperscript{29}. 


Consistent with the inequalities in OSA discussed above, poorer health outcomes have been reported in AAs and HAs compared to EAs with OSA. AAs with OSA symptoms report higher rates of excessive daytime sleepiness as well as poorer sleep quality and physical health. Elderly AAs have higher rates of abnormal 24-hour blood pressure profiles (nocturnal non-dipping blood pressure), independent of obesity and severity of OSA. Observational data from a clinical cohort and a general population survey suggest the risk of hypertension is higher in AAs. In contrast, the risk of hypertension in OSA was not found to vary significantly by race in the Sleep Heart Health Study, a younger community-based predominantly EA cohort. Severe OSA is associated with risk of peripheral arterial disease only in AAs. Within AAs, OSA is independently associated with higher prevalence of hypertension, diabetes and in women with cellular senescence (telomere shortening). Moderate to severe OSA has been associated with abnormal fasting glucose levels in AAs and EAs but not HAs. However, HAs with moderate to severe OSA report poorer mental health and are at increased risk for diabetes.

The mechanisms underlying these racial inequalities in OSA are not well understood. Obesity is the strongest risk factor for OSA and is rooted in both environmental and genetic factors, varying significantly by race. Although the association of genetic risk loci for obesity with OSA traits remain to be described, it is plausible that racial inequalities in OSA are mediated in part by genetic and environmental factors that drive higher rates of obesity in AAs and HAs. The majority of studies in OSA adjust for BMI, but while the heritability estimates for BMI in AAs are similar to EAs, the role of fat distribution (parapharyngeal and abdominal fat) remains unclear. There are two recent reports identifying novel OSA genetic risk loci with genome-wide significance in HAs and another quantitative trait locus for non-rapid eye movement sleep AHI in men of diverse racial backgrounds. In contrast, genome-wide association studies (GWAS) in EAs and AAs have not yet identified any OSA genetic loci.
meeting genome-wide significance criteria though the sample sizes used have been smaller and this remains an area of active investigation. Linkage analyses and candidate gene studies have reported differences in OSA risk loci between AAs and EAs, but the sample sizes for replication have been underpowered. There are few studies examining the role of craniofacial characteristics as an explanatory factor in racial OSA inequalities. While brachycephaly is an important mediator of OSA risk in EA, enlarged tongue and soft tissue are reported to mediate the propensity for OSA in AAs. Although AAs have smaller upper airway dimensions, the heritability of this trait in AAs is similar to EAs. There is little data regarding racial differences in OSA phenotypes with respect to respiratory control, upper airway collapsibility and arousal threshold or racial differences in the physiological responses to perturbations in OSA (chronic intermittent hypoxia, sleep fragmentation and sympathetic activation). AAs have lower vital capacity and more hypoxemic attenuation of baroresponse in sleep than EAs, but these results have not been replicated, so the implications of these findings remain unclear.

In summary, the prevalence and severity of OSA is higher in AA’s and likely in HA’s, independent of obesity. Thus far, limited data indicate that the risk of adverse health outcomes such as daytime sleepiness and cardiometabolic outcomes may also be higher in these populations. It is important to note that socioeconomic status (SES), neighborhood disadvantage, and poverty have been shown to mediate the elevated risk of OSA in AAs, underscoring the importance of considering and controlling for psychosocial factors in future studies of racial inequalities.

### Inequalities in Insomnia

Overall, minorities are at a higher risk for insomnia compared to EAs. When self-reported insomnia is examined specifically in AA (and in HA’s in some studies), the prevalence is either lower than in EAs or largely explained by SES and psychosocial stressors. The
importance of SES as a mediator of sleep quality can also be gleaned from two studies done on college students, in which education and health between racial groups should be comparable. These studies used validated questionnaires and found equivalent or lower prevalence of insomnia in AAs\textsuperscript{66,67}. On the other hand, physician-diagnosed insomnia rates, sleep quality by validated questionnaires and quantitative measures indicate poorer sleep quality, particularly in urban AAs\textsuperscript{60,68-71}. Thus, racial inequalities related to insomnia reveal paradoxical findings, which highlight the role complex mediators and cultural beliefs may play on self-reported symptoms (Table 2). In addition to the consideration of the multilevel factors noted above and their interactions, future use of high throughput wearable technologies and genetic ancestry to add quantitative measures of sleep quality, bio-geographical ancestry to population surveillance and clinical association studies will advance our understanding of racial inequalities in insomnia.

### Inequalities in Narcolepsy

Narcolepsy is a rare, central disorder of hypersomnolence characterized by excessive daytime sleepiness, cataplexy, hypnagogic hallucinations, sleep paralysis, and abnormal rapid eye movement (REM) sleep, and is caused by a lack of hypocretin/orexin\textsuperscript{72}. Genetic studies of narcolepsy reveal certain commonalities and differences across racial populations including AAs and EAs (Table 3). In most, but not all studies\textsuperscript{73}, AAs are more frequently DRB1*15 (DR2) negative than EAs\textsuperscript{74-76}. A number of studies have shown the human leukocyte antigen (HLA) DQB1*0602 rather than DRB1*15 (DR2) is the unifying, most strongly associated susceptibility allele across racial groups including AAs and EAs\textsuperscript{75-79}. In AAs, the association is stronger with DQB1*06:02 since linkage disequilibrium, the nonrandom pattern of association between alleles at different loci within a population, is not as high between DQB1*0602 and DRB1*1501, indicating greater independence of these alleles\textsuperscript{76,78}. Significant effects of other HLA-DQ alleles also have been reported across racial groups. In AAs, narcolepsy is associated with
DQB1*0602 haplotypes bearing distinct DRB1 alleles, most commonly DRB1*1503, DRB1*1501, DRB1*1101, and DRB1*0806. In addition, the DRB1*13, DQA1*0103, and DQB1*0603 haplotypes confer moderate protection in EAs and AAs.

Beyond the HLA genes, other risk genes have also been implicated in the development of narcolepsy in various racial/ethnic groups (Table 3). Associations between narcolepsy and polymorphisms in the TCRA locus, in the P2RY11 gene, and in the EIF3g gene have been found in AAs and EAs.

A few studies conducted to date have investigated the prevalence and clinical phenotypic expression of narcolepsy by race. The prevalence of DQB1*0602 in narcolepsy was much higher in AAs than in EAs, although in normal healthy adult sleepers, the prevalence of this risk allele did not differ significantly between these racial groups. Notably, heterozygous or homozygous DQB1*0602 allele status influenced risk and disease expression in AAs and EAs. Thus, frequency differences of the DQB1*0602 risk haplotype in racial groups indicate environmental factors contribute to the development of narcolepsy and thus may explain differences in narcolepsy prevalence. Indeed, two studies found a higher prevalence of diagnosed narcolepsy with cataplexy in AAs compared with EAs. In narcoleptics with cataplexy, AAs and EAs showed similar symptomatology, age of onset, and symptom severity, but had minor differences in severe sleep paralysis, reports of cataplexy affecting the jaw and arms and being triggered by negative emotions, and reports of going blank due to sleep attacks. In general clinic and hypersomnia groups, AAs, compared to EAs were 2.8-4.0 times as likely to have a sleep-onset REM period on polysomnography, after controlling for other significant variables. Another study found that sex ratio, polysomnographic and multiple sleep latency test (MSLT) measures did not differ between AAs and EAs, although AAs with narcolepsy had higher DQB1*0602 positivity, earlier symptom onset and more severe daytime
sleepiness\textsuperscript{72}. AAs also had lower cerebrospinal fluid hypocretin-1 levels and lower rates of cataplexy\textsuperscript{72,90}.

Beyond racial differences, there is a paucity of research for other health inequalities in narcolepsy. One study found a higher prevalence of diagnosed narcolepsy with cataplexy in households with lower educational attainment and lower annual income\textsuperscript{87}. Another study found students with a history of adverse childhood experiences had higher mean scores on subjective sleep disorder measures of narcolepsy than those without such experiences\textsuperscript{91}. Longitudinal studies among diverse populations are needed to understand this association and to investigate potential racial inequalities in the strength of this association\textsuperscript{92}.

In summary, there are well established racial differences in narcolepsy, with genetic underpinnings. Since both environmental and genetic factors underlie racial inequalities, genetic ancestry is an ideal method for future studies in AAs and other admixed groups with narcolepsy to parse the genetic aspects of race from the cultural, behavioral, and social aspects that may underlie observed phenotypic differences. Such parsing could facilitate symptom identification and diagnosis of narcolepsy.

Inequalities in Chronotype, Circadian Parameters and Circadian Rhythm Sleep Disorders

Chronotype (also referred to as morningness-eveningness or diurnal preference), which shows considerable inter-individual variation, is the tendency to be an early “lark” (alert and preferring to be active early in the day) or a late “owl” (alert and preferring to be active later in the day). Several studies have found racial differences in chronotype and associated circadian parameters (Table 4). Further, chronotype differences have been found between HA subgroups\textsuperscript{93} and between Europeans and Africans\textsuperscript{94,95}. Using experimental studies, Eastman and colleagues found robust differences between AAs and EAs in basic properties of the circadian clock, including endogenous or free-running circadian period and the magnitude of
phase advances and delays, which can contribute to morningness-eveningness, with self-
identification techniques\textsuperscript{96,97}. Using genetic ancestry, differences in circadian period, chronotype
and responses to shifts in the sleep-wake cycle, between these two racial groups have been
reported\textsuperscript{98-100}. Of interest, circadian period correlated with percentage of African and European
genetic ancestry, whereby longer circadian periods were associated with a greater percentage
of European ancestry and a smaller percentage of African ancestry. There was also sex by
ancestry differences: EA women had a shorter circadian period than men, but there was no sex
difference in circadian period between AA men and women. The aforementioned racial
differences suggest there could be racial inequalities in disease risk, in response to jet lag or
shiftwork and/or in the development of circadian rhythm based sleep disorders
(CRSDs)\textsuperscript{94,95,97,100}. In contrast to chronotype or circadian parameters, however, there are no
published studies of racial inequalities in CRSDs, which are extreme clinical variants of
chronotype, and include advanced and delayed sleep phase disorders.

The genetic underpinnings of chronotype and CRSDs have been well studied, although
only a few studies have examined racial differences in core circadian clock genes. Three GWASs
have identified genetic components of chronotype, although all used European ancestry
populations\textsuperscript{101,102}, and nearly all candidate gene studies of chronotype or advanced and delayed
sleep phase disorders have used individuals of European or Asian ancestry, with little
investigation of admixed groups such as AAs or HAs\textsuperscript{102,103}. Of note, two studies have found racial
differences in the frequencies of polymorphisms of core clock genes associated with chronotype
and with CRSDs\textsuperscript{104,105}.

In summary, despite extensive knowledge of the genetics of chronotype and CRSDs,
studies examining racial differences are limited but promising. Given such findings, a better
understanding of the prevalence of circadian rhythm perturbations by race and the extent to
which genetic differences underlie racial differences in phenotypes such as chronotype and circadian period are critical areas of health inequalities research.

**Genetic Ancestry and Admixture Mapping: Application in Understanding Sleep Health Inequality**

Although outside the scope of this review, the importance of social determinants of health in mediation of racial health inequalities must be emphasized. With respect to inequalities in health behaviors, polygenic traits and chronic diseases, social determinants of health such as education, lifestyle, living and work situations, income, environmental pollution, public policy, discrimination, and psychosocial stress can have a profound impact and should be considered in research and in practice. As an overview, a schematic conceptual model is presented (Figure 1) outlining the multilevel genesis of racial sleep health inequalities.

DNA sequence is identical across more than 99.4% of sites across the human genome, and genetic diversity ranges widely across human populations, being greatest among populations with recent African ancestry. The genomes of continental populations since the migration of humans out of Africa have diverged primarily because of genetic drift or natural random fluctuations of allele frequencies, with some contribution from natural selection acting differentially across continental populations and from the emergence of new population-specific mutations. Admixed populations such as AAs and HAs, with recent ancestry from two or three continental populations, bring together combinations of these diverse genomes, and therefore carry substantial genetic variation that can contribute to phenotypic traits and health inequalities. Genetic ancestry in admixed AAs and HAs can be measured reliably using as few as 400 Ancestry Informative Markers (AIMs), which are single nucleotide polymorphisms that vary widely in allele frequency across ancestral populations from different continents. Analysis of these markers in combination provides estimates of the proportion of ancestry from...
each contributing ancestral population, or average ‘global ancestry’ across the genome\textsuperscript{112,113}. For example, AAs typically have ~80% recent African and ~20% recent European ancestry, whereas African, European and Amerindian ancestry proportions vary widely in HAs based on different admixture events and the number of generations since the admixture event\textsuperscript{107,114}. As genome-wide genotypes become more readily available, global genetic ancestry is increasingly calculated using genome-wide data, which provides improved accuracy to differentiate between closely-related populations compared to specifically selected AIMS\textsuperscript{111}.

Genetic ancestry is a powerful tool to search for biological contributions to health inequalities in admixed populations\textsuperscript{110}. Association of global ancestry estimates with sleep disorder prevalence and severity, or with differential response to sleep medications, signals that ancestry-specific risk or protective genetic factors are present. Importantly, ancestry-directed studies searching for genetic factors need to adequately control for other risk and social factors such as socioeconomic status\textsuperscript{115}. Further, statistical power will depend on heritability of the trait, strength of ancestry-specific effects and sample size. For example, African genetic ancestry estimated by ~1700 AIMS in 70 AAs was found to be associated with highly heritable indices of sleep depth (slow-wave sleep and delta power) but this study may have been underpowered to detect genetic ancestry effects in less heritable sleep duration and sleep efficiency traits\textsuperscript{116}.

If prevalence and severity of a sleep trait vary by ancestry, admixture mapping can identify genomic regions that track with disease in one ancestral population\textsuperscript{117}. Admixture mapping relies on the concept of ‘local ancestry’, where the ancestral origin of each chromosomal segment in the mosaic genome of an individual can be quantified on the basis of polymorphisms with highly differentiated allele frequencies in the ancestral populations\textsuperscript{118}. In a case only admixture mapping study design, affected individuals from an admixed population are scanned for regions of the genome that deviate in local ancestry from genome-wide averages.
In a case-control study design or for quantitative traits, regression models are used to test the association of local ancestry with disease status or trait levels\textsuperscript{117}. Admixture mapping has been used successfully to identify genetic associations for several traits, e.g. multiple sclerosis\textsuperscript{119}, chronic kidney disease\textsuperscript{120} and pharmacogenetics of relapse of acute lymphocytic leukemia\textsuperscript{121}. Advantages of admixture mapping include: 1) the requirement of low-density genomic coverage to identify genetic signals, leading to a lower multiple testing burden relative to GWAS; 2) the ability to aggregate evidence from multiple independently associated variants in a region of local ancestry, even if these variants are not directly genotyped; and 3) the opportunity to detect regions with functional variants that have undergone selection in one of the ancestral populations. However, admixture mapping requires follow-up genotyping and association testing to identify specific contributing genetic variants in the identified regions. Further, analysis for some HA groups remain challenging, because computational methods that detect three-way admixture are rare, and ancestral populations for HAs are often not well known or represented in public sequence datasets\textsuperscript{122,123}.

Newer methods combine independent association evidence from admixture mapping with single variant association tests in admixture-informed GWAS to enhance the power to detect novel genetic signals in admixed populations\textsuperscript{124,125}, or can identify new gene-gene or gene-environment interactions that arise based on the new combination of genomes or environmental contexts in admixed populations\textsuperscript{126}, and these could be useful tools in the effort to identify biological contributors to sleep inequalities in AA and HA populations.

Beyond gene discovery, follow up studies of newly discovered sleep disorder loci in AA and HA populations are expected to be useful to: 1) test if genetic effects for sleep disorders generalize or are consistent across different US populations\textsuperscript{127}; 2) fine-map or narrow the genomic interval in which causal variants lie\textsuperscript{128}; 3) estimate polygenic risk for sleep disorders or pharmacogenetic response to medications that may have implications for personalized
screening, prevention or therapy in AA and HA populations, and 4) investigate the impact of sleep genetic factors on related comorbidities that contribute to health inequality.

Conclusions

Substantial inequalities exist in a wide range of sleep phenotypes and sleep disorders that may contribute to overall health inequalities given the impact of poor sleep on a wide range of psychiatric, neurocognitive, metabolic and cardiovascular health outcomes. Exploiting these inequalities in admixed populations such as AAs and HAs may prove to be a powerful tool to identify underlying genetic variants predisposing to sleep disorders, thereby providing important insights into the molecular pathogenesis of these diseases. For admixture studies to be statistically robust in identifying causal genetic variants, the studies must control for cultural, socioeconomic, or other environmental differences and be adequately powered to detect differences in risk between ancestral populations due to differences in the prevalence of the causal genetic variants. Our current understanding of OSA and insomnia both in terms of the magnitude of health inequalities and the extent to which these inequalities are due to genetic variants suggest that very large sample sizes will be required for ancestry studies to be helpful. In contrast, ancestry studies in narcolepsy and circadian rhythm sleep disorders/chronotype, because they putatively have a much larger genetic underpinning, may be more fruitful. Future studies using admixture-informed approaches hold great promise in identifying and ultimately addressing biological contributions to sleep health inequalities in these settings. Furthermore, because sleep health inequalities result in a disproportional impact on health in minority populations, it is vital that future genetic studies include these racial groups so that subsequent knowledge gained from such research can be applied directly to those populations who would derive the greatest benefit.
Grant Support

Preparation of this review was supported by VA CSR and D (1IK2CX001026-01; B. Prasad), National Institutes of Health (NIH R01 DK117488; N. Goel, NIH R01 DK107859; R. Saxena, NIH HL127307; S.R. Patel), and National Aeronautics and Space Administration (NNX14AN49G; N. Goel).
References:


2. 2015 National Healthcare Quality and Disparities Report and 5th Anniversary Update on the National Quality Strategy


50 Sutherland K, Lee RW, Cistulli PA. Obesity and craniofacial structure as risk factors for obstructive sleep apnoea: impact of ethnicity. Respirology 2012; 17:213-222
64 Slopen N, Williams DR. Discrimination, other psychosocial stressors, and self-reported sleep duration and difficulties. Sleep 2014; 37:147-156


75 Mignot E, Lin X, Arrigoni J, et al. DQB1*0602 and DQA1*0102 (DQ1) are better markers than DR2 for narcolepsy in Caucasian and black Americans. Sleep 1994; 17:560-67

76 Rogers AE, Meehan J, Guilleminault C, et al. HLA DR15 (DR2) and DQB1*0602 typing studies in 188 narcoleptic patients with cataplexy. Neurology 1997; 48:1550-1556

77 Mignot E, Hayduk R, Black J, et al. HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients. Sleep 1997; 20:1012-1020


85 Watson NF, Ton TG, Koepsell TD, et al. Does narcolepsy symptom severity vary according to HLA-DQB1*0602 allele status? Sleep 2010; 33:29-35

87 Koepsell TD, Longstreth WT, Ton TG. Medical exposures in youth and the frequency of narcolepsy with cataplexy: a population-based case-control study in genetically predisposed people. J Sleep Res 2010; 19:80-86
89 Cairns A, Bogan R. Prevalence and Clinical Correlates of a Short Onset REM Period (SOREMP) during Routine PSG. Sleep 2015; 38:1575-1581
91 Chambers E, Belicki K. Using sleep dysfunction to explore the nature of resilience in adult survivors of childhood abuse or trauma. Child Abuse Negl 1998; 22:753-758
99 Eastman CI, Tomaka VA, Crowley SJ. Circadian rhythms of European and African-Americans after a large delay of sleep as in jet lag and night work. Sci Rep 2016; 6:36716
100 Eastman CI, Tomaka VA, Crowley SJ. Sex and ancestry determine the free-running circadian period. J Sleep Res 2017; 26:547-550
102 Goel N. Genetic Markers of Sleep and Sleepiness. Sleep Med Clin 2017; 12:289-299
103 Goel N. Genetics of Sleep Timing, Duration and Homeostasis in Humans. Sleep Med Clin 2011; 6:171-182
109 Chakraborty R, Weiss KM. Admixture as a tool for finding linked genes and detecting that difference from allelic association between loci. Proc Natl Acad Sci U S A 1988; 85:9119-9123
110 Halder I, Shriver MD. Measuring and using admixture to study the genetics of complex diseases. Hum Genomics 2003; 1:52-62
Table 1. Health Inequalities in Sleep Apnea

<table>
<thead>
<tr>
<th>Author/Ref #</th>
<th>Year</th>
<th>Study Design</th>
<th>Sample</th>
<th>Measurements</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ancoli-Israel</td>
<td>1995</td>
<td>Cross-sectional, n= 400</td>
<td>&gt;65 years old, population based cohort</td>
<td>HSAT</td>
<td>AA race was associated with two fold increased risk of severe OSA.</td>
</tr>
<tr>
<td>Kripke</td>
<td>1997</td>
<td>Cross-sectional, n= 355</td>
<td>40-64 years, population based cohort</td>
<td>Home oximetry</td>
<td>Prevalence of OSA was three times higher in HA, AA and Other (mostly Asian) race.</td>
</tr>
<tr>
<td>Redline</td>
<td>1997</td>
<td>Cross-sectional, n= 847</td>
<td>2-86 years, genetic-epidemiology cohort</td>
<td>HSAT</td>
<td>Prevalence of OSA was higher in younger AAs (&lt; 25 years, adjusted OR 1.8).</td>
</tr>
<tr>
<td>Redline</td>
<td>1999</td>
<td>Cross-sectional, n= 399</td>
<td>2-18 years, genetic-epidemiology cohort</td>
<td>HSAT</td>
<td>AA children had higher adjusted prevalence of OSA (OR 3.5).</td>
</tr>
<tr>
<td>Stepansky</td>
<td>1999</td>
<td>Case-control</td>
<td>&lt;17 years</td>
<td>PSG</td>
<td>AA children with similar BMI had more severe oxygen desaturation.</td>
</tr>
<tr>
<td>Meetze</td>
<td>2002</td>
<td>Retrospective cross-sectional, n= 280</td>
<td>Age &gt; 18 years, Single center, clinical cohort</td>
<td>PSG</td>
<td>AA women with OSA were younger and had higher BMI and prevalence of hypertension, AA men had more severe oxygen desaturation.</td>
</tr>
<tr>
<td>Young</td>
<td>2002</td>
<td>Cross-sectional, n= 5615</td>
<td>&gt;40 years old, Sleep Heart Health Study</td>
<td>Home PSG</td>
<td>Race was not associated with risk of OSA</td>
</tr>
<tr>
<td>Rosen</td>
<td>2003</td>
<td>Cross-sectional, n= 850</td>
<td>8-11 years, population based cohort</td>
<td>HSAT</td>
<td>AA children had 3.5 fold increased adjusted risk of moderate OSA.</td>
</tr>
<tr>
<td>Goodwin</td>
<td>2003</td>
<td>Cross-sectional, n= 239</td>
<td>Age 6-11 years, Community based cohort</td>
<td>Home PSG</td>
<td>HA or EA race was not associated OSA risk or severity.</td>
</tr>
<tr>
<td>Scharf</td>
<td>2004</td>
<td>Cross-sectional, n= 233</td>
<td>Retrospective clinical cohort</td>
<td>PSG</td>
<td>AAs had more severe OSA; this risk was mediated by income and BMI.</td>
</tr>
<tr>
<td>Ruiter</td>
<td>2010</td>
<td>Meta-analysis</td>
<td>Prevalence from pooled sample, n = 2,534,882 Severity from pooled sample, n = 6182</td>
<td>Mixed methods</td>
<td>Higher prevalence (effect size 0.13) and greater severity (effect size 0.10) of OSA in AAs.</td>
</tr>
<tr>
<td>Ramos</td>
<td>2011</td>
<td>Prospective cohort study, n = 1,964</td>
<td>Elderly, age 75 ± 9 years</td>
<td>Questionnaires</td>
<td>HAs had higher risk for snoring (OR 3.6) and daytime sleepiness (OR 2.8), but no difference for AAs.</td>
</tr>
<tr>
<td>Pranathiageswaran</td>
<td>2013</td>
<td>Prospective, observational study, n = 512</td>
<td>Adults, Single center, clinical cohort</td>
<td>PSG</td>
<td>Young and middle aged AA men had higher AHI after adjustment for BMI.</td>
</tr>
<tr>
<td>Weinstock</td>
<td>2014</td>
<td>Cross-sectional, n= 464</td>
<td>5 to 10 years, with OSA</td>
<td>PSG</td>
<td>20% increase in AHI in AA children; adjusted for BMI.</td>
</tr>
<tr>
<td>Ramos</td>
<td>2014</td>
<td>Prospective, observational study, n = 176</td>
<td>Adults, Single center, hospitalized patients with acute stroke</td>
<td>Berlin Questionnaire</td>
<td>HAs were at higher risk (OR 2.6), AAs had equivalent risk for OSA.</td>
</tr>
<tr>
<td>Chen</td>
<td>2015</td>
<td>Cross-sectional, Age 54-93 years,</td>
<td>Home PSG</td>
<td>AAs had higher odds of OSA; OR = 1.78, short sleep; OR =</td>
<td></td>
</tr>
<tr>
<td>Study</td>
<td>Year</td>
<td>Design</td>
<td>Sample Size</td>
<td>Methodology</td>
<td>Results</td>
</tr>
<tr>
<td>-------</td>
<td>------</td>
<td>--------</td>
<td>-------------</td>
<td>-------------</td>
<td>---------</td>
</tr>
<tr>
<td>Cakirer &amp;</td>
<td>2001</td>
<td>Cross-sectional, n = 364 EA and 165 AA</td>
<td>Adults, Cleveland Family Study</td>
<td>HSAT</td>
<td>Brachycephaly, measured by anthropometric calipers, was associated with AHI in EAs but not in AAs.</td>
</tr>
<tr>
<td>Ancoli-Israel &amp;</td>
<td>2002</td>
<td>Prospective clinical cohort, n = 70 each of AA and EA</td>
<td>Age 65 to 93 years</td>
<td>Home actigraphy plus respiratory test</td>
<td>AAs had higher blood pressure dipping ratios (&quot;non-dipping&quot;) after adjustment for AHI and BMI.</td>
</tr>
<tr>
<td>Nieto &amp;</td>
<td>2002</td>
<td>Cross-sectional, n = 6,132</td>
<td>&gt;40 years old Sleep Heart Health Study</td>
<td>Home PSG</td>
<td>Risk of hypertension was associated with severity of OSA, but not race. * 77% of the cohort was EA, with &lt;10% in other racial categories.</td>
</tr>
<tr>
<td>Spilsbury &amp;</td>
<td>2006</td>
<td>Cross-sectional, n = 843</td>
<td>Age 8-11 years</td>
<td>HSAT</td>
<td>AAs were more likely to have OSA (OR 3.9) which was reduced to OR of 1.9 (0.8-4.6) with adjustment for neighborhood disadvantage.</td>
</tr>
<tr>
<td>Surani &amp;</td>
<td>2009</td>
<td>Cross-sectional, n = 172</td>
<td>Single center clinical cohort</td>
<td>PSG</td>
<td>HAs with OSA had twofold increased prevalence of diabetes.</td>
</tr>
<tr>
<td>Baldwin &amp;</td>
<td>2010</td>
<td>Cross-sectional, n = 5,237</td>
<td>Age &gt;40 years, Sleep Heart Health Study</td>
<td>Home PSG</td>
<td>AAs with frequent snoring, insomnia symptoms or EDS had poorer physical health. HAs with frequent snoring, insomnia symptoms or EDS had poorer mental health.</td>
</tr>
<tr>
<td>Baron &amp;</td>
<td>2010</td>
<td>Cross-sectional, n = 5,173</td>
<td>Mean age 66 years</td>
<td>ESS</td>
<td>Risk of EDS was higher in AAs (OR 1.8-2.0) with OSA.</td>
</tr>
<tr>
<td>Alkhazna &amp;</td>
<td>2011</td>
<td>Cross-sectional, n = 280</td>
<td>Adult, Single center clinical cohort</td>
<td>PSG</td>
<td>OSA severity did not vary by race, but AA had higher prevalence of hypertension.</td>
</tr>
<tr>
<td>Fulop &amp;</td>
<td>2012</td>
<td>Cross-sectional, n = 5,301</td>
<td>AA cohort</td>
<td>Modified Berlin Questionnaire</td>
<td>Risk of OSA in AA men and women was associated with co-morbid hypertension and diabetes after adjustment for BMI, neck and waist circumference.</td>
</tr>
<tr>
<td>Sands-Lincoln &amp;</td>
<td>2013</td>
<td>Cross-sectional, n = 4,418</td>
<td>Adults, 2007-2008 NHANES survey data</td>
<td>Questionnaire</td>
<td>OSA symptoms were associated with risk of hypertension in overweight AA (OR 4.7), overweight EA (OR 1.6) and obese HA (OR 2).</td>
</tr>
<tr>
<td>Redline &amp;</td>
<td>2014</td>
<td>Cross-sectional, n = 14,440</td>
<td>Age 45-74 years, Hispanic Community Health Study</td>
<td>HSAT</td>
<td>Overall prevalence in HA was 25.8% for mild OSA; 9.8% for moderate OSA; 3.9% for severe OSA. Moderate-severe OSA were at higher risk for hypertension (OR 1.4) and diabetes (OR 1.9).</td>
</tr>
<tr>
<td>Bakker &amp;</td>
<td>2015</td>
<td>Cross-sectional, n = 2,151</td>
<td>Mean age 68.5 ± 9.2 years, population based cohort</td>
<td>Home PSG</td>
<td>Moderate-to-severe OSA was associated with abnormal fasting glucose in AAs (OR 2.14) and EAs (OR 2.85), but not among HAs, after adjusting for age, sex, waist circumference, and sleep duration.</td>
</tr>
<tr>
<td>Study</td>
<td>Year</td>
<td>Study Design</td>
<td>Sample Size</td>
<td>Mean Age</td>
<td>Measurement</td>
</tr>
<tr>
<td>-------</td>
<td>------</td>
<td>--------------</td>
<td>-------------</td>
<td>----------</td>
<td>-------------</td>
</tr>
<tr>
<td>Turner²²</td>
<td>2016</td>
<td>Two cohorts, n = 943 AA, n = 452 EA</td>
<td>Mean age 80 ± 7.8 years, population based cohort</td>
<td>Berlin Questionnaire</td>
<td>OSA risk was not different but sleep quality was poorer in AA elderly.</td>
</tr>
<tr>
<td>Nagayoshi²²</td>
<td>2016</td>
<td>Cross-sectional, n = 1,844</td>
<td>Mean age 68 years, population based cohort</td>
<td>Home PSG</td>
<td>Severe OSA was associated with higher prevalence of peripheral arterial disease in AA.</td>
</tr>
<tr>
<td>Wang²⁵</td>
<td>2017</td>
<td>Cross-sectional, n = 774</td>
<td>Mean age 7 ± 1.4 years, Clinical cohort</td>
<td>PSG</td>
<td>Association between race and AHI was mediated by socioeconomic variables including poverty.</td>
</tr>
</tbody>
</table>

**KEY:** Ref # = In text reference number, African American = AA, Hispanic American = HA, European American = EA, Obstructive Sleep Apnea = OSA, Apnea-Hypopnea Index = AHI, Body Mass Index = BMI, Polysomnography = PSG, Home Sleep Apnea Test = HSAT, Odds Ratio = OR, Epworth Sleepiness Scale = ESS, Excessive Daytime Sleepiness = EDS. *Comparison group European Americans (EAs) unless otherwise specified.*
<table>
<thead>
<tr>
<th>Author/Ref #</th>
<th>Year</th>
<th>Study Design</th>
<th>Sample</th>
<th>Measurements</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bixler</td>
<td>2002</td>
<td>Cross-sectional, n=1,741</td>
<td>Age &gt; 20 years, population based cohort</td>
<td>Self-reported symptoms</td>
<td>Non-EAs (OR 2.0) was significantly associated with risk of insomnia.</td>
</tr>
<tr>
<td>Allen</td>
<td>2008</td>
<td>Survey, n=1,910</td>
<td>Age &gt;65 years, rural population based cohort</td>
<td>Adapted validated questionnaire</td>
<td>AAs reported similar frequency of insomnia.</td>
</tr>
<tr>
<td>Mezick</td>
<td>2008</td>
<td>Cross-sectional, n=187</td>
<td>Age 45-75 years, population based cohort</td>
<td>PSQI, home PSG and Actigraphy</td>
<td>AAs had less SE, SWS, and poorer sleep quality. This effect was mediated by SES.</td>
</tr>
<tr>
<td>Ruiter</td>
<td>2010</td>
<td>Meta-analysis</td>
<td>Pooled sample of &gt;8000</td>
<td>Mixed methods</td>
<td>AAs were less likely to report insomnia symptoms (ES -0.19 for WASO and -0.23 for sleep complaints).</td>
</tr>
<tr>
<td>Patel</td>
<td>2008</td>
<td>Cross-sectional, n=9,714</td>
<td>Age &gt; 18 years, population based sample</td>
<td>Self-reported symptoms</td>
<td>AAs and HAs reported poor sleep quality (OR 1.59, and 1.65, respectively) and this was mediated by SES.</td>
</tr>
<tr>
<td>Grandner</td>
<td>2010</td>
<td>Survey, n=159,856</td>
<td>Age &gt;18 years, population based sample</td>
<td>Self-reported symptoms</td>
<td>AA and HA women were less likely to report insomnia symptoms (OR 0.74 for each).</td>
</tr>
<tr>
<td>Ram</td>
<td>2010</td>
<td>Cross-sectional, n=6,139</td>
<td>2005-2006 NHANES</td>
<td>Physician diagnosed and self-reported symptoms</td>
<td>AAs and HAs (≥1.5% vs. 0.8%) had higher rates of physician diagnosed insomnia, but less self-reported WASO.</td>
</tr>
<tr>
<td>Gaultney</td>
<td>2010</td>
<td>Survey, n=1,845</td>
<td>College students</td>
<td>Validated questionnaire</td>
<td>AA students reported less risk for insomnia and poor sleep practices.</td>
</tr>
<tr>
<td>Pigeon</td>
<td>2011</td>
<td>Cross sectional clinical cohort, n=92</td>
<td>Mean age 52 years</td>
<td>PSQI</td>
<td>AAs were more likely to experience sleep disturbance (OR 2.4) after adjustment for education, depression and chronic illness.</td>
</tr>
<tr>
<td>Grandner</td>
<td>2012</td>
<td>Cross sectional, n=7,148</td>
<td>Age &gt;18 years, population based cohort</td>
<td>Self-reported symptoms</td>
<td>Perceived racial discrimination in healthcare setting was associated with increased risk of sleep disturbance (OR 1.60, p = .04) in AAs.</td>
</tr>
<tr>
<td>Singareddy</td>
<td>2012</td>
<td>Prospective with follow up of 7.5 years, n=1,246</td>
<td>Age ≥ 20 years, population based cohort</td>
<td>Self-reported symptoms</td>
<td>Non-EAs were more likely (OR 2.8) to develop incident insomnia independent of SES, physical and mental health.</td>
</tr>
<tr>
<td>Grandner</td>
<td>2013</td>
<td>Cross sectional, n=4,081</td>
<td>2007-2008 NHANES</td>
<td>Self-reported symptoms</td>
<td>AAs were more likely to report prolonged sleep latency (adjusted OR 1.6). AAs and HAs were less likely to report insomnia symptoms (adjusted OR 0.56 to 0.82).</td>
</tr>
<tr>
<td>Hicken</td>
<td>2013</td>
<td>Cross-sectional survey, n=3,105</td>
<td>Age &gt; 18 years, Urban population based sample</td>
<td>Self-reported symptoms</td>
<td>AAs reported more insomnia symptoms. This was mediated by SES and racism-related vigilance. Similar trends were observed in HAs.</td>
</tr>
<tr>
<td>Petrov</td>
<td>2014</td>
<td>Survey, n=1,684</td>
<td>College students</td>
<td>Validated questionnaire</td>
<td>Prevalence of insomnia was not different in AAs.</td>
</tr>
<tr>
<td>Slopen</td>
<td>2014</td>
<td>Cross-sectional, n=2,983</td>
<td>Age &gt; 18 years, Urban population based sample</td>
<td>Self-reported symptoms</td>
<td>Discrimination mediates sleep duration and sleep difficulty in AAs and HAs, independent of SES and other psychosocial stressors.</td>
</tr>
<tr>
<td>Carnethon</td>
<td>2016</td>
<td>Observational, Age 35-64 years, urban</td>
<td>Actigraphy, PSQI</td>
<td>AAs had significantly lower SE, greater sleep fragmentation</td>
<td>AAs had significantly lower SE, greater sleep fragmentation</td>
</tr>
</tbody>
</table>
and poorer self-reported sleep quality adjusted for SES and health indicators.

**KEY:** Ref # = In text reference number, African American = AA, Hispanic American = HA, European American = EA, Socioeconomic Status = SES, Total Sleep Time = TST, Sleep Efficiency = SE, Slow Wave Sleep = SWS, Wake After Sleep Onset = WASO, National Health and Nutrition Examination Survey = NHANES, Obstructive Sleep Apnea = OSA, Polysomnography = PSG, Pittsburgh Sleep Quality Index = PSQI, Odds Ratio = OR, Effect Size = ES. *Comparison group European Americans (EAs) unless otherwise specified.*
<table>
<thead>
<tr>
<th>Author/Ref#</th>
<th>Year</th>
<th>Study Design</th>
<th>Sample</th>
<th>Measurements</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kramer*3</td>
<td>1987</td>
<td>Cross-sectional, n = 14</td>
<td>36-74 years old, narcoleptic patients</td>
<td>Genotyping</td>
<td>100% of EAs and AAs were positive for DRB1<em>15 (DR2) indicating association between DRB1</em>15 (DR2) and narcolepsy. No differences between races.</td>
</tr>
<tr>
<td>Neely*4</td>
<td>1987</td>
<td>Cross-sectional, n = 18 AA with narcolepsy; n = 99 AA controls</td>
<td>Adults, narcoleptic patients from Sleep Clinic in Chicago</td>
<td>Genotyping</td>
<td>33% AA narcoleptics did not have DRB1*15 (DR2), which was lower than historic EAs. 100% AAs and EAs had DQw1. 22% AAs had DQw1 but without DR2. 100% of historic EAs, had both DR2 and DQw1.</td>
</tr>
<tr>
<td>Mignot*5</td>
<td>1994</td>
<td>Retrospective, n = 47</td>
<td>Adults, narcolepsy patients with cataplexy, from U.S. and international university-based sleep clinics and laboratories</td>
<td>Genotyping</td>
<td>95% EAs, but only 11% AAs, were DRB1<em>1501 (DR2) positive, 68% AAs, 0% EAs carried DRB1</em>1503. DQB1<em>0602 was found in 96% AAs and 95% EAs. DQB1</em>0602 was more sensitive marker for narcolepsy than DRB1*15 (DR2) in AAs and EAs.</td>
</tr>
<tr>
<td>Rogers*6</td>
<td>1997</td>
<td>Retrospective, n = 188</td>
<td>Adults, narcolepsy patients with cataplexy, from Stanford database</td>
<td>Genotyping</td>
<td>67.2% AAs were positive for DRB1<em>15, compared with 84.5% EAs. In AAs, association was stronger with DQB1</em>06:02. DQB1<em>0602 was more sensitive marker for narcolepsy with cataplexy than DRB1</em>15 (DR2) in AAs and EAs.</td>
</tr>
<tr>
<td>Mignot*7</td>
<td>1997</td>
<td>Cross-sectional, n = 509</td>
<td>18-68 years old, narcolepsy patients enrolled in clinical trial for modafinil</td>
<td>Genotyping</td>
<td>DQB1<em>0602 positivity was significantly higher in AAs. DQB1</em>0602 was more sensitive marker for narcolepsy than DRB1*15 (DR2) in AAs and EAs.</td>
</tr>
<tr>
<td>Mignot*8</td>
<td>2001</td>
<td>Retrospective population-based case-control study, n = 420 narcolepsy with cataplexy, n = 1087 controls</td>
<td>Adults, narcolepsy patients with cataplexy, from U.S. and international university-based sleep clinics and laboratories</td>
<td>Genotyping</td>
<td>DQB1<em>0602 positivity was significantly higher in AAs. In AAs, association was stronger with DQB1</em>0602. DRB1<em>13, DQA1</em>0103, DQB1*0603 haplotypes conferred moderate protection in EAs and AAs.</td>
</tr>
<tr>
<td>Pelin*9</td>
<td>1998</td>
<td>Cross-sectional, n = 669</td>
<td>Adults, narcoleptic patients from Stanford database and multi-center clinical trial for modafinil</td>
<td>Genotyping</td>
<td>Both EAs and AAs with or without cataplexy who were homozygous for HLA-DQB1<em>0602 had relative risks 2-4 times higher compared with HLA-DQB1</em>0602 heterozygotes. No differences in severity with increasing allelic dosage in EAs or AAs.</td>
</tr>
<tr>
<td>Mignot*10</td>
<td>1997</td>
<td>Retrospective, n = 58</td>
<td>Adults, non-DRB1*15 narcolepsy patients with cataplexy, from Stanford database</td>
<td>Genotyping</td>
<td>In AAs, narcolepsy was associated with rare DQB1<em>0602 haplotypes bearing distinct DRB1 alleles, most commonly DRB1</em>1503, DRB1<em>1501, DRB1</em>1101, and DRB1*0806.</td>
</tr>
<tr>
<td>Hallmayer*11</td>
<td>2009</td>
<td>Case-control GWAS, n = 807 cases, n = 1074 controls; replication: n = 1057 cases, n = 1104 controls</td>
<td>Adults, clinical cohorts from various national and international sleep clinics and laboratories</td>
<td>Genotyping</td>
<td>Association of narcolepsy within the TCRA locus polymorphisms in three ethnic groups, including EAs and AAs.</td>
</tr>
<tr>
<td>Kornum*12</td>
<td>2011</td>
<td>Case-control GWAS, n = 1074 controls</td>
<td>Adults, clinical cohorts</td>
<td>Genotyping</td>
<td>Association of narcolepsy with a SNP in the P2RY11 gene in</td>
</tr>
</tbody>
</table>
cases and n = 1074 controls; n = 1858 cases and n = 2384 controls from various national and international sleep clinics and laboratories.

<table>
<thead>
<tr>
<th>Reference</th>
<th>Year</th>
<th>Study Design</th>
<th>Sample Size</th>
<th>Controls</th>
<th>Methods</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Holm et al.</td>
<td>2015</td>
<td>Case-control GWAS, EA: n = 807 cases, n = 1074 controls; Chinese: n = 1078 cases, n = 1903 controls; AA: n = 249 cases, n = 1048 controls from various national and international sleep clinics and laboratories.</td>
<td>Adults, clinical cohorts from various national and international sleep clinics and laboratories</td>
<td>Genotyping</td>
<td>Association of narcolepsy with a SNP in the EIF3G gene in three ethnic groups, including EAs and AAs.</td>
<td></td>
</tr>
<tr>
<td>Longstreth et al.</td>
<td>2009</td>
<td>Retrospective population-based study, n = 425 narcolepsy</td>
<td>&gt;18 years old, positive for DQB1*0602 allele, King County, Washington</td>
<td>Questionnaires, interviews, genotyping</td>
<td>Higher prevalence of narcolepsy with cataplexy in AAs.</td>
<td></td>
</tr>
<tr>
<td>Koepsell et al.</td>
<td>2010</td>
<td>Retrospective population-based case-control study, n = 45 narcolepsy with cataplexy, n = 95 controls</td>
<td>Ages 18-50 years, positive for the DQB1*0602 allele, King County, Washington</td>
<td>Questionnaires, interviews, genotyping</td>
<td>Higher prevalence of diagnosed narcolepsy cases in AAs than EAs (OR = 8.1). Higher prevalence of diagnosed narcolepsy in households with lower educational attainment and lower annual income.</td>
<td></td>
</tr>
<tr>
<td>Okun et al.</td>
<td>2002</td>
<td>Retrospective cross-sectional, n = 484</td>
<td>Mean age, 43.1 years old, diagnosis of narcolepsy-cataplexy</td>
<td>ESS, MSLT, PSG, genotyping, hypocretin-1 level</td>
<td>AAs and EAs showed similar symptomatology, age of onset, and disease severity. Minor differences in other variables: EA had less severe slow paralysis and more reports of cataplexy affecting jaw and arms than AAs. AAs had more reports of negative emotions triggering cataplexy and going blank due to sleep attacks.</td>
<td></td>
</tr>
<tr>
<td>Cairns et al.</td>
<td>2015</td>
<td>Retrospective cross-sectional, n = 3,059 suspected hypersomnia, n = 79,651 general sleep clinic sample</td>
<td>&gt;18 years old, repository of scored and physician interpreted records</td>
<td>MSLT, PSG</td>
<td>AAs were 2.8-4 times as likely to have a PSG SOREMP, controlling for other significant variables.</td>
<td></td>
</tr>
<tr>
<td>Kawai et al.</td>
<td>2015</td>
<td>Retrospective cross-sectional, n = 1097</td>
<td>Children and adults, diagnosed with narcolepsy, Stanford Center for Narcolepsy Research database</td>
<td>ESS, MSLT, PSG, genotyping, hypocretin-1 level</td>
<td>Sex ratio, PSG, and MSLT measures did not differ between AAs and EAs. ESS score was higher and age of onset of sleepiness was earlier in AAs. HLA-DQB1*0602 positivity was higher in AAs but CSF hypocretin-1 level was more frequently low (&lt;110 pg/ml) in AAs. In patients with low CSF hypocretin-1, AAs were 4.5 fold more likely to be without cataplexy.</td>
<td></td>
</tr>
<tr>
<td>Andlauer et al.</td>
<td>2012</td>
<td>Retrospective population-based case-control study, n = 171 narcolepsy with cataplexy, n = 170 control narcolepsy without cataplexy</td>
<td>&gt;18 years old, University-based sleep clinics and laboratories</td>
<td>ESS, MSLT, PSG, genotyping, hypocretin-1 level</td>
<td>Patients with low CSF hypocretin-1 level (&lt;110 pg/ml) were more likely to be AAs vs. EAs: 1% of normal-CSF-hypocretin-1 vs. 20% of low-CSF-hypocretin-1 cases were AAs, OR = 28.</td>
<td></td>
</tr>
<tr>
<td>Chambers et al.</td>
<td>1988</td>
<td>Cross-sectional, n = 97</td>
<td>Mean age, 21.6 years old, Canadian university students</td>
<td>Sleep Disorders Questionnaire</td>
<td>Abuse/trauma group scored more negatively than controls for narcolepsy (mean, 25.8 vs. 21.1; p &lt;.01).</td>
<td></td>
</tr>
</tbody>
</table>

**KEY:** Ref # = In text reference number, African American = AA, European American = EA, Genome-Wide Association Study = GWAS, Odds Ratio = OR, Epworth Sleepiness Scale = ESS, Multiple Sleep Latency Test = MSLT, Polysomnography = PSG, Single Nucleotide Polymorphism = SNP, Sleep Onset Rapid Eye Movement Period = SOREMP.
Cerebrospinal Fluid= CSF. *Comparison group European Americans (EAs) unless otherwise specified.*

<p>| Table 4. Health Inequalities in Chronotype and Circadian Parameters |
|-----------------------------------------------|----------------|---------------------------------|---------------------------------------|
| <strong>Author/Ref#</strong> | <strong>Year</strong> | <strong>Study Design</strong> | <strong>Sample</strong> | <strong>Measurements</strong> | <strong>Results</strong> |
| Knutson# | 2017 | Cross-sectional, n = 113,429 | Ages 18-74 years, self-identified Hispanic/Latino | Self-reported bedtimes and wake times. Chronotype defined as midpoint of sleep on weekends adjusted for sleep duration on | Significant differences between various HA groups, with Mexican Americans having earliest chronotype, bedtimes and waketimes. |</p>
<table>
<thead>
<tr>
<th>Reference</th>
<th>Year</th>
<th>Study Design</th>
<th>Sample Size</th>
<th>Sample Characteristics</th>
<th>Measurement of Circadian Period</th>
<th>Chronotype Method</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Malone $^{94}$</td>
<td>2016</td>
<td>Cross sectional, n = 439,933</td>
<td>Ages 40-69 years, UK Biobank study</td>
<td>Chronotype via single item in which participants rated themselves as definitely a morning person, more a morning than an evening person, more an evening than a morning person, definitely an evening person.</td>
<td>Morning vs. intermediate chronotype was 1.4 times more prevalent in self-identified Africans than Whites in the UK.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Malone $^{95}$</td>
<td>2017</td>
<td>Cross sectional, n = 2044</td>
<td>Ages 40-69 years, UK Biobank study</td>
<td>Chronotype via single item in which participants rated themselves as definitely a morning person, more a morning than an evening person, more an evening than a morning person, definitely an evening person.</td>
<td>Africans had a 62% greater odds of being morning chronotype than Whites in the UK.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smith $^{96}$</td>
<td>2009</td>
<td>Experimental, n = 60</td>
<td>29 males, ages 18-45 years</td>
<td>Circadian period, circadian phase advances and delays via DLMO measurements.</td>
<td>AAs had significantly shorter circadian periods. AAs had larger phase advances and smaller phase delays.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eastman $^{97}$</td>
<td>2012</td>
<td>Experimental, n = 94</td>
<td>45 males, ages 18-42 years</td>
<td>Circadian period via DLMO measurements. Chronotype via MEQ.</td>
<td>AAs had significantly shorter circadian periods. MEQ scores did not differ between races.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eastman $^{98}$</td>
<td>2015</td>
<td>Experimental, n = 36</td>
<td>19 males, ages 21-43 years</td>
<td>Circadian period, circadian phase shifts via DLMO measurements. Chronotype via MEQ.</td>
<td>AAs defined by genetic ancestry had significantly shorter circadian periods. Longer circadian periods were associated with greater percentage of European ancestry and smaller percentage of African ancestry. EAs had larger phase shifts after 9-h advance than AAs, but were more likely to phase delay. MEQ scores did not differ between races.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eastman $^{99}$</td>
<td>2016</td>
<td>Experimental, n = 45</td>
<td>22 males, ages 18-44 years</td>
<td>Circadian period, circadian phase shifts via DLMO measurements. Chronotype via MEQ.</td>
<td>AAs defined by genetic ancestry had significantly shorter circadian periods and an earlier chronotype (more morningness). EAs had larger phase delays than AAs after 9-h delay.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eastman $^{100}$</td>
<td>2017</td>
<td>Experimental, n = 63</td>
<td>31 males, ages 18-44 years</td>
<td>Circadian period, circadian phase shifts via DLMO measurements.</td>
<td>AAs defined by genetic ancestry had significantly shorter circadian periods. EA women had shorter circadian periods than men, but there was no sex difference in AAs.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**KEY:** Ref # = In text reference number, African American= AA, Hispanic American= HA, European American= EA, UK= United Kingdom, Dim Light Melatonin Onset= DLMO, Morningness-Eveningness Questionnaire= MEQ. *Comparison group European Americans (EAs) unless otherwise specified.*
Figure 1. Conceptual model for multilevel genesis of sleep health inequalities
CIH: chronic intermittent hypoxia. CRSD: circadian rhythm sleep disorders. Solid arrows indicate relationships supported by human studies. Dashed arrows indicate hypothetical or animal data supported relationships.